Compare Adaptive Biotechnologies Corp (ADPT) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Hut 8 Corp — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while Hut 8 Corp trades at $90.2 (market cap $10.94B). The key difference: Hut 8 Corp is far larger — about 2.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | HUT | |
|---|---|---|
Market Cap | $4.04B | $10.94B |
Sector | Health | Technology |
52-Week High | $25.45 | $133.02 |
52-Week Low | $12.30 | $21.37 |
Enterprise Value | $4.10B | $18.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
HUT trades at $93.91, up 9.63% today amid a broader neocloud stock rally. The stock shows bearish technical signals with support at $87 and resistance at $92. Fundamentally, revenue grew 81% year-over-year in Q2 2026 to $74 million, but net losses persist with a -188.59% margin. The company is transitioning to an AI data center focus, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (93.75%) and a $165.11 price target reflect optimism in AI infrastructure growth, but high valuation ratios and persistent losses pose risks. Execution on Beacon Point commercialization and debt management are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
